Remicade and Xarelto woes haven't stopped J&J hiking forecast by Arlene Weintraub Tuesday, April 17, 2018 Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.
Torrent drops out of Sanofi EU generics auction over price: report by Eric Sagonowsky Thursday, April 5, 2018 Sanofi is out another potential buyer for its European generics business as India-based Torrent Pharma exited deal talks, according to a report.
After two high-profile M&A fails, how did Sanofi win Bioverativ? by Tracy Staton Friday, February 9, 2018 Sanofi didn't just woo Bioverativ execs. It made a play with investor Alex Denner. The result? $85M for CEO John Cox and a 2018 EPS boost for Sanofi.
Gritstone, Inovio and more—News of Note by Eric Sagonowsky Tuesday, January 23, 2018 Here is some other vaccine news of note for the week.
Shire draws pharma suitors as tax reform nears: report by Eric Sagonowsky Wednesday, December 20, 2017 Top pharma companies are circling Shire for a potential buy, The Telegraph reports, just as U.S. tax changes are expected to fill M&A war chests.
Pharma's M&A scouts aim to pick up the pace in 2018 by Eric Sagonowsky Wednesday, December 20, 2017 Now that Republicans in Congress have passed tax reform, the pharma sector could be due for a long-anticipated M&A rebound.
Novartis CEO says most biotech deals are just too expensive by Eric Sagonowsky Wednesday, July 19, 2017 Novartis is hunting for bolt-on deals, but too-high biotech valuations have forced its M&A scouts to eye early-stage assets.
